Adjuvant Pembrolizumab for Renal Cell Carcinoma (keynote-564): Exploratory Analysis Across Ucla Integrated Staging System Risk Groups and Disease Stage
Year: 2024
Type: article
Authors: Tian Zhang, Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Lei Xu, Kentaro Imai, Christian Poehlein, Thomas Powles
Institutions: The University of Texas Southwestern Medical Center, Harvard University, Dana-Farber Cancer Institute, Poznan University of Medical Sciences, Samsung Medical Center, Sungkyunkwan University, Beatson West of Scotland Cancer Centre, University of Glasgow, Fiona Stanley Hospital, Edinburgh Cancer Research, University of Edinburgh, University Hospital Ostrava, Taipei Veterans General Hospital, Asan Medical Center, University of Ulsan, Imperial College Healthcare NHS Trust, Centre Hospitalier Universitaire de Besançon, Hôpital Saint-André, Fundación Arturo López Pérez, University of Pennsylvania Health System, Abramson Cancer Center, Provincial Polyclinical Hospital in Toruń, Merck & Co., Inc., Rahway, NJ, USA (United States), Queen Mary University of London, Barts Health NHS Trust, The Royal Free Hospital, Barts Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4392807968